{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:08Z","timestamp":1792782668201,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the National Natural Science Foundation of China","award":["82200177"],"award-info":[{"award-number":["82200177"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the National Natural Science Foundation of China","award":["82170218, 82470221, 82103917, 82400264\uff0c82470127"],"award-info":[{"award-number":["82170218, 82470221, 82103917, 82400264\uff0c82470127"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"National Key Research and Development Program of China","award":["No. 2022YFC2502700"],"award-info":[{"award-number":["No. 2022YFC2502700"]}]},{"name":"Suzhou Key project","award":["DZXYJ202305, SZS201615, SZS2023014, SKY2022012"],"award-info":[{"award-number":["DZXYJ202305, SZS201615, SZS2023014, SKY2022012"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-026-07164-0","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:45:18Z","timestamp":1783925118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The clinical relevance of RAS pathway gene mutations in childhood B-cell acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Xiaoyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixin","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yizhen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaoyan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"1","key":"7164_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A (2019) Cancer statistics, 2019. CA Cancer J Clin 69(1):7\u201334. https:\/\/doi.org\/10.3322\/caac.21551","journal-title":"CA Cancer J Clin"},{"issue":"15","key":"7164_CR2","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1200\/jco.20.02262","volume":"39","author":"NN Shah","year":"2021","unstructured":"Shah NN, Lee DW, Yates B, Yuan CM, Shalabi H, Martin S et al (2021) Long-term follow-up of CD19-CAR T-cell therapy in children and young adults with B-all. J Clin Oncol 39(15):1650\u20131659. https:\/\/doi.org\/10.1200\/jco.20.02262","journal-title":"J Clin Oncol"},{"issue":"8","key":"7164_CR3","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1200\/jco.23.01392","volume":"42","author":"A Hodder","year":"2024","unstructured":"Hodder A, Mishra AK, Enshaei A, Baird S, Elbeshlawi I, Bonney D et al (2024) Blinatumomab for first-line treatment of children and young persons with B-all. J Clin Oncol 42(8):907\u2013914. https:\/\/doi.org\/10.1200\/jco.23.01392","journal-title":"J Clin Oncol"},{"issue":"22","key":"7164_CR4","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1200\/jco.2015.64.6364","volume":"34","author":"R Pieters","year":"2016","unstructured":"Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E et al (2016) Successful therapy reduction and intensification for childhood acute lymphoblastic leukemia based on minimal residual disease monitoring: Study ALL10 from the dutch childhood oncology group. J Clin Oncol 34(22):2591\u20132601. https:\/\/doi.org\/10.1200\/jco.2015.64.6364","journal-title":"J Clin Oncol"},{"issue":"3","key":"7164_CR5","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/leu.2017.265","volume":"32","author":"N Toft","year":"2018","unstructured":"Toft N, Birgens H, Abrahamsson J, Gri\u0161kevi\u010dius L, Hallb\u00f6\u00f6k H, Heyman M et al (2018) Results of NOPHO ALL2008 treatment for patients aged 1\u201345 years with acute lymphoblastic leukemia. Leukemia 32(3):606\u2013615. https:\/\/doi.org\/10.1038\/leu.2017.265","journal-title":"Leukemia"},{"issue":"6","key":"7164_CR6","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s11684-020-0759-8","volume":"14","author":"CH Pui","year":"2020","unstructured":"Pui CH (2020) Precision medicine in acute lymphoblastic leukemia. Front Med 14(6):689\u2013700. https:\/\/doi.org\/10.1007\/s11684-020-0759-8","journal-title":"Front Med"},{"issue":"1","key":"7164_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1186\/s12943-025-02455-y","volume":"24","author":"F Lo Schiavo","year":"2025","unstructured":"Lo Schiavo F, Salvesi C, Jandoubi M, Pirini F, Garbetta J, Martinelli G et al (2025) Novel molecular mechanisms of FLT3 deregulation: from the acute myeloid leukemia experience to therapeutic insights in acute lymphoblastic leukemia. Mol Cancer 24(1):266. https:\/\/doi.org\/10.1186\/s12943-025-02455-y","journal-title":"Mol Cancer"},{"issue":"9","key":"7164_CR8","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1038\/s41588-022-01159-z","volume":"54","author":"SW Brady","year":"2022","unstructured":"Brady SW, Roberts KG, Gu Z, Shi L, Pounds S, Pei D et al (2022) The genomic landscape of pediatric acute lymphoblastic leukemia. Nat Genet 54(9):1376\u20131389. https:\/\/doi.org\/10.1038\/s41588-022-01159-z","journal-title":"Nat Genet"},{"key":"7164_CR9","doi-asserted-by":"publisher","first-page":"1505060","DOI":"10.3389\/fped.2024.1505060","volume":"12","author":"ER Biojone","year":"2024","unstructured":"Biojone ER, Guido BC, Cavalcante LLM, Dos Santos J\u00fanior ACM, de Pontes RM, Furtado FM et al (2024) Prevalence of FLT3 gene mutation and its expression in Brazilian pediatric B-ALL patients: clinical implications. Front Pediatr 12:1505060. https:\/\/doi.org\/10.3389\/fped.2024.1505060","journal-title":"Front Pediatr"},{"key":"7164_CR10","doi-asserted-by":"publisher","unstructured":"Haage TR, Schraven B, Mougiakakos D, Fischer T (2023) How ITD insertion sites orchestrate the biology and disease of FLT3-ITD-mutated acute myeloid leukemia. Cancers (Basel) 15(11). https:\/\/doi.org\/10.3390\/cancers15112991","DOI":"10.3390\/cancers15112991"},{"issue":"4","key":"7164_CR11","doi-asserted-by":"publisher","first-page":"e28899","DOI":"10.1002\/pbc.28899","volume":"68","author":"YJ Huang","year":"2021","unstructured":"Huang YJ, Liu HC, Jaing TH, Wu KH, Wang SC, Yen HJ et al (2021) RAS pathway mutation is an added-value biomarker in pediatric Philadelphia-negative B-cell acute lymphoblastic leukemia with IKZF1 deletions. Pediatr Blood Cancer 68(4):e28899. https:\/\/doi.org\/10.1002\/pbc.28899","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"7164_CR12","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1182\/bloodadvances.2021005634","volume":"6","author":"TH Tran","year":"2022","unstructured":"Tran TH, Langlois S, Meloche C, Caron M, Saint-Onge P, Rouette A et al (2022) Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16\u2009\u2013\u2009001. Blood Adv 6(4):1329\u20131341. https:\/\/doi.org\/10.1182\/bloodadvances.2021005634","journal-title":"Blood Adv"},{"issue":"3","key":"7164_CR13","doi-asserted-by":"publisher","first-page":"e3265","DOI":"10.1002\/hon.3265","volume":"42","author":"X Li","year":"2024","unstructured":"Li X, Lin S, Liao N, Mai H, Long X, Liu L et al (2024) The RAS-signaling-pathway-mutation-related prognosis in B-cell acute lymphoblastic leukemia: A report from South China children\u2019s leukemia group. Hematol Oncol 42(3):e3265. https:\/\/doi.org\/10.1002\/hon.3265","journal-title":"Hematol Oncol"},{"issue":"4","key":"7164_CR14","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/sj.leu.2403272","volume":"18","author":"JP Perentesis","year":"2004","unstructured":"Perentesis JP, Bhatia S, Boyle E, Shao Y, Shu XO, Steinbuch M et al (2004) RAS oncogene mutations and outcome of therapy for childhood acute lymphoblastic leukemia. Leukemia 18(4):685\u2013692. https:\/\/doi.org\/10.1038\/sj.leu.2403272","journal-title":"Leukemia"},{"issue":"12","key":"7164_CR15","doi-asserted-by":"publisher","first-page":"13886","DOI":"10.18632\/oncotarget.7356","volume":"7","author":"M Messina","year":"2016","unstructured":"Messina M, Chiaretti S, Wang J, Fedullo AL, Peragine N, Gianfelici V et al (2016) Prognostic and therapeutic role of targetable lesions in B-lineage acute lymphoblastic leukemia without recurrent fusion genes. Oncotarget 7(12):13886\u201313901. https:\/\/doi.org\/10.18632\/oncotarget.7356","journal-title":"Oncotarget"},{"key":"7164_CR16","doi-asserted-by":"publisher","unstructured":"Felice MS, Rubio PL, Digiorge J, Barreda Frank M, Mart\u00ednez CS, Guitter MR et al (2022) Impact of IKZF1 deletions in the prognosis of childhood acute lymphoblastic leukemia in Argentina. Cancers (Basel) 14(13). https:\/\/doi.org\/10.3390\/cancers14133283","DOI":"10.3390\/cancers14133283"},{"key":"7164_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-025-026","author":"RW Wang\u2019ondu","year":"2025","unstructured":"Wang\u2019ondu RW, Ashcraft E, Chang TC, Roberts KG, Brady SW, Fan Y et al (2025) Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia. https:\/\/doi.org\/10.1038\/s41375-025-026","journal-title":"Leukemia"},{"issue":"9","key":"7164_CR18","doi-asserted-by":"publisher","first-page":"3544","DOI":"10.1182\/blood-2003-07-2441","volume":"103","author":"SA Armstrong","year":"2004","unstructured":"Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA et al (2004) FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103(9):3544\u20133546. https:\/\/doi.org\/10.1182\/blood-2003-07-2441","journal-title":"Blood"},{"issue":"50","key":"7164_CR19","doi-asserted-by":"publisher","first-page":"E11711","DOI":"10.1073\/pnas.1814397115","volume":"115","author":"JF Li","year":"2018","unstructured":"Li JF, Dai YT, Lilljebj\u00f6rn H, Shen SH, Cui BW, Bai L et al (2018) Transcriptional landscape of B cell precursor acute lymphoblastic leukemia based on an international study of 1,223 cases. Proc Natl Acad Sci U S A 115(50):E11711\u2013e20. https:\/\/doi.org\/10.1073\/pnas.1814397115","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"20","key":"7164_CR20","doi-asserted-by":"publisher","first-page":"5165","DOI":"10.1182\/bloodadvances.2019001307","volume":"4","author":"H Ueno","year":"2020","unstructured":"Ueno H, Yoshida K, Shiozawa Y, Nannya Y, Iijima-Yamashita Y, Kiyokawa N et al (2020) Landscape of driver mutations and their clinical impacts in pediatric B-cell precursor acute lymphoblastic leukemia. Blood Adv 4(20):5165\u20135173. https:\/\/doi.org\/10.1182\/bloodadvances.2019001307","journal-title":"Blood Adv"},{"issue":"2","key":"7164_CR21","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/s41416-023-02511-8","volume":"130","author":"A Gutierrez-Camino","year":"2024","unstructured":"Gutierrez-Camino A, Richer C, Ouimet M, Fuchs C, Langlois S, Khater F et al (2024) Characterisation of FLT3 alterations in childhood acute lymphoblastic leukaemia. Br J Cancer 130(2):317\u2013326. https:\/\/doi.org\/10.1038\/s41416-023-02511-8","journal-title":"Br J Cancer"},{"issue":"4","key":"7164_CR22","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/leu.2017.303","volume":"32","author":"IS Jerchel","year":"2018","unstructured":"Jerchel IS, Hoogkamer AQ, Ari\u00ebs IM, Steeghs EMP, Boer JM, Besselink NJM et al (2018) RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia 32(4):931\u2013940. https:\/\/doi.org\/10.1038\/leu.2017.303","journal-title":"Leukemia"},{"issue":"1","key":"7164_CR23","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1038\/s41467-025-56229-7","volume":"16","author":"Z Li","year":"2025","unstructured":"Li Z, Zhao H, Yang W, Maillard M, Yoshimura S, Hsiao YC et al (2025) Molecular and pharmacological heterogeneity of ETV6::RUNX1 acute lymphoblastic leukemia. Nat Commun 16(1):1153. https:\/\/doi.org\/10.1038\/s41467-025-56229-7","journal-title":"Nat Commun"},{"issue":"7","key":"7164_CR24","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1038\/s41375-025-02633-3","volume":"39","author":"RW Wang\u2019ondu","year":"2025","unstructured":"Wang\u2019ondu RW, Ashcraft E, Chang TC, Roberts KG, Brady SW, Fan Y et al (2025) Heterogeneity of IKZF1 genomic alterations and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia. Leukemia 39(7):1595\u20131606. https:\/\/doi.org\/10.1038\/s41375-025-02633-3","journal-title":"Leukemia"},{"issue":"4","key":"7164_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/leu.2017.303","volume":"32","author":"IS Jerchel","year":"2018","unstructured":"Jerchel IS, Hoogkamer AQ, Ari\u00ebs IM, Steeghs EMP, Boer JM, Besselink NJM et al (2018) RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia. Leukemia 32(4):931\u2013940","journal-title":"Leukemia"},{"key":"7164_CR26","doi-asserted-by":"publisher","unstructured":"Liang DC, Chen SH, Liu HC, Yang CP, Yeh TC, Jaing TH et al (2018) Mutational status of NRAS, KRAS, and PTPN11 genes is associated with genetic\/cytogenetic features in children with B-precursor acute lymphoblastic leukemia. Pediatr Blood Cancer 65(2). https:\/\/doi.org\/10.1002\/pbc.26786","DOI":"10.1002\/pbc.26786"},{"issue":"5","key":"7164_CR27","doi-asserted-by":"publisher","first-page":"827","DOI":"10.21037\/tp-22-512","volume":"12","author":"LFY Al-Kzayer","year":"2023","unstructured":"Al-Kzayer LFY, Saeed RM, Ghali HH, Tanaka M, Al-Jadiry MF, Faraj SA et al (2023) Comprehensive genetic analyses of childhood acute leukemia in Iraq using next-generation sequencing. Transl Pediatr 12(5):827\u2013844. https:\/\/doi.org\/10.21037\/tp-22-512","journal-title":"Transl Pediatr"},{"key":"7164_CR28","doi-asserted-by":"publisher","unstructured":"Medina KL (2022) Flt3 signaling in B lymphocyte development and humoral immunity. Int J Mol Sci 23(13). https:\/\/doi.org\/10.3390\/ijms23137289","DOI":"10.3390\/ijms23137289"},{"issue":"1\u20132","key":"7164_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41417-019-0120-z","volume":"27","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhang Y, Wang F, Wang M, Liu H, Chen X et al (2020) The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia. Cancer Gene Ther 27(1\u20132):81\u201388. https:\/\/doi.org\/10.1038\/s41417-019-0120-z","journal-title":"Cancer Gene Ther"},{"issue":"1","key":"7164_CR30","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41375-021-01323-0","volume":"36","author":"FG R\u00fccker","year":"2022","unstructured":"R\u00fccker FG, Du L, Luck TJ, Benner A, Krzykalla J, Gathmann I et al (2022) Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia 36(1):90\u201399. https:\/\/doi.org\/10.1038\/s41375-021-01323-0","journal-title":"Leukemia"},{"issue":"15","key":"7164_CR31","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1200\/jco.23.01061","volume":"42","author":"ES Wang","year":"2024","unstructured":"Wang ES, Goldberg AD, Tallman M, Walter RB, Karanes C, Sandhu K et al (2024) Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML. J Clin Oncol 42(15):1776\u20131787. https:\/\/doi.org\/10.1200\/jco.23.01061","journal-title":"J Clin Oncol"},{"issue":"2","key":"7164_CR32","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1038\/labinvest.2016.142","volume":"97","author":"M Kiuru","year":"2017","unstructured":"Kiuru M, Busam KJ (2017) The NF1 gene in tumor syndromes and melanoma. Lab Invest 97(2):146\u2013157. https:\/\/doi.org\/10.1038\/labinvest.2016.142","journal-title":"Lab Invest"},{"key":"7164_CR33","doi-asserted-by":"publisher","unstructured":"Karaconji T, Whist E, Jamieson RV, Flaherty MP, Grigg JRB (2019) Neurofibromatosis type 1: Review and update on emerging therapies. Asia-Pacific J Ophthalmol 8(1). https:\/\/doi.org\/10.22608\/APO.2018182","DOI":"10.22608\/APO.2018182"},{"issue":"49","key":"7164_CR34","doi-asserted-by":"publisher","first-page":"5626","DOI":"10.1038\/onc.2013.506","volume":"33","author":"ME Brundage","year":"2014","unstructured":"Brundage ME, Tandon P, Eaves DW, Williams JP, Miller SJ, Hennigan RH et al (2014) MAF mediates crosstalk between Ras-MAPK and mTOR signaling in NF1. Oncogene 33(49):5626\u20135636. https:\/\/doi.org\/10.1038\/onc.2013.506","journal-title":"Oncogene"},{"issue":"1","key":"7164_CR35","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/annonc\/mdy497","volume":"30","author":"ES Sokol","year":"2019","unstructured":"Sokol ES, Feng YX, Jin DX, Basudan A, Lee AV, Atkinson JM et al (2019) Loss of function of NF1 is a mechanism of acquired resistance to endocrine therapy in lobular breast cancer. Ann Oncol 30(1):115\u2013123. https:\/\/doi.org\/10.1093\/annonc\/mdy497","journal-title":"Ann Oncol"},{"issue":"3","key":"7164_CR36","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3324\/haematol.2020.269431","volume":"107","author":"T Kaburagi","year":"2022","unstructured":"Kaburagi T, Yamato G, Shiba N, Yoshida K, Hara Y, Tabuchi K et al (2022) Clinical significance of RAS pathway alterations in pediatric acute myeloid leukemia. Haematologica 107(3):583\u2013592. https:\/\/doi.org\/10.3324\/haematol.2020.269431","journal-title":"Haematologica"},{"issue":"1","key":"7164_CR37","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1038\/s41467-025-57077-1","volume":"16","author":"A Safonov","year":"2025","unstructured":"Safonov A, Nomakuchi TT, Chao E, Horton C, Dolinsky JS, Yussuf A et al (2025) A genotype-first approach identifies high incidence of NF1 pathogenic variants with distinct disease associations. Nat Commun 16(1):3121. https:\/\/doi.org\/10.1038\/s41467-025-57077-1","journal-title":"Nat Commun"},{"issue":"1","key":"7164_CR38","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1111\/ejh.14419","volume":"115","author":"H Tariq","year":"2025","unstructured":"Tariq H, Loxas M, Alikhan MB, Gao J, Lu X, Chen QC et al (2025) Clinicopathologic characteristics and prognostic profile of chronic myeloid neoplasms with somatic NF1 mutations in adult patients. Eur J Haematol 115(1):46\u201356. https:\/\/doi.org\/10.1111\/ejh.14419","journal-title":"Eur J Haematol"},{"issue":"3","key":"7164_CR39","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/bjh.13142","volume":"168","author":"R Sutton","year":"2015","unstructured":"Sutton R, Shaw PJ, Venn NC, Law T, Dissanayake A, Kilo T et al (2015) Persistent MRD before and after allogeneic BMT predicts relapse in children with acute lymphoblastic leukaemia. Br J Haematol 168(3):395\u2013404. https:\/\/doi.org\/10.1111\/bjh.13142","journal-title":"Br J Haematol"},{"issue":"11","key":"7164_CR40","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1182\/blood.2019000893","volume":"134","author":"C Bueno","year":"2019","unstructured":"Bueno C, Tejedor JR, Bashford-Rogers R, Gonz\u00e1lez-Silva L, Vald\u00e9s-Mas R, Agraz-Dobl\u00e1s A et al (2019) Natural history and cell of origin of TC F3-ZN F384 and PTPN11 mutations in monozygotic twins with concordant BCP-ALL. Blood 134(11):900\u2013905. https:\/\/doi.org\/10.1182\/blood.2019000893","journal-title":"Blood"},{"issue":"12","key":"7164_CR41","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3324\/haematol.2020.259226","volume":"106","author":"\u017d Anti\u0107","year":"2021","unstructured":"Anti\u0107 \u017d, Yu J, Van Reijmersdal SV, Van Dijk A, Dekker L, Segerink WH et al (2021) Multiclonal complexity of pediatric acute lymphoblastic leukemia and the prognostic relevance of subclonal mutations. Haematologica 106(12):3046\u20133055. https:\/\/doi.org\/10.3324\/haematol.2020.259226","journal-title":"Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07164-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07164-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:02:42Z","timestamp":1791378162000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-026-07164-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":41,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2026,11]]}},"alternative-id":["7164"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07164-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8082043\/v1","asserted-by":"object"}]},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"443"}}